MolDX Declines Coverage for Renal Cell Carcinoma Biomarker Tests
Short answer: MolDX's draft LCD DL40429 denies Medicare coverage for transcriptional biomarker tests used to guide renal cell carcinoma treatment decisions, citing retrospective, outdated evidence skewed toward clear-cell histology. It's the one non-coverage outcome among three LCDs MolDX posted together in late August 2026 — the other two, covering blood-cancer NGS and genome-wide structural variant testing, both got positive coverage.
What MolDX actually decided
MolDX — the molecular diagnostics program run jointly by Medicare Administrative Contractors Palmetto GBA, CGS Administrators, and Noridian Healthcare Solutions — posted draft LCD DL40429, titled "MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal Carcinoma," as part of a batch of three draft and final LCDs released in late August 2026, according to an analysis of the coverage documents published by health-policy blog Discoveries in Health Policy. The request behind DL40429 dates back to May 11, 2022, meaning the underlying coverage question sat with MolDX for more than four years before a determination was posted. Unlike its two companion policies from the same batch, DL40429 lands as non-covered.
Why the evidence fell short
MolDX's stated reasoning is specific, not a generic denial. Per the draft language cited by Discoveries in Health Policy, the contractor found the supporting studies "often retrospective or outdated, dominated by clear-cell RCC, limited by incomplete clinical-pathologic data and tumor heterogeneity." The determination goes further, stating the evidence is "insufficient to show that the classifiers add clinically meaningful information beyond stage, grade, histology, and established nomograms or actually improve management and outcomes." MolDX also flagged a timing problem that cuts across most legacy prognostic-classifier evidence in oncology right now: "the rapidly changing RCC treatment landscape, particularly immunotherapy, further weakens older evidence." A classifier validated against a pre-immunotherapy treatment paradigm is, in MolDX's read, answering a question that no longer matches how patients are actually managed.
This isn't MolDX's first prognostic-classifier test
Renal carcinoma is not the first solid-tumor category where MolDX has had to weigh a prognostic or predictive molecular classifier against its published technical assessment framework. MolDX's LCD for prognostic and predictive molecular classifiers in bladder cancer (L38576/L38649) has been active since July 18, 2021 and was most recently revised effective April 16, 2026, according to the CMS Medicare Coverage Database. That policy covers qualifying tests only when a patient is a candidate for multiple treatment options, when the test predicts response to a specific therapy consistent with NCCN, ASCO, SUO, or AUA guidelines, and when the lab has demonstrated analytical validity, clinical validity, and clinical utility showing "a clear and significant biological/molecular basis for stratifying patients," among eight total conditions. It took years of accumulating evidence for bladder cancer classifiers to clear that bar. RCC classifiers, per DL40429, have not yet cleared the equivalent one — not because the underlying biology is implausible, but because the published evidence base has not caught up to how RCC is actually treated today.
MolDX's stated path back to coverage
DL40429 is not a permanent door-closing. MolDX outlined, in the same draft, what it would take for a renal carcinoma transcriptional classifier to clear the bar: the test must address a genuine treatment choice rather than restate known risk; it must materially improve recurrence or metastasis risk prediction beyond what stage, grade, histology, and existing nomograms already provide; it must be independently validated in more than one dataset; it must demonstrate clinical utility — that using the test actually changes management or outcomes — in peer-reviewed literature; it must pass MolDX's own technical assessment for analytical validity; and it must perform comparably to, or better than, already-covered alternatives. For test developers and lab medical directors, that list functions as a de facto evidence-generation roadmap, not just a rejection notice.
What this means for labs and ordering clinicians right now
For laboratories currently offering or developing transcriptional biomarker panels for RCC treatment planning, DL40429 means Medicare will not reimburse the test under this LCD as drafted, regardless of how the result is used clinically. That has immediate billing and prior-authorization implications: claims should not be submitted expecting Medicare payment for RCC prognostic classifiers covered by this determination, and revenue cycle teams should flag existing orders for review. It does not mean the underlying science is wrong — MolDX's own reasoning frames this as an evidence-maturity problem, not a validity verdict, and explicitly ties the weakness to how fast RCC's immunotherapy-driven treatment landscape has moved past older validation cohorts. Ordering oncologists and urologists should not assume a negative Medicare LCD equals a negative clinical recommendation from professional societies, and should continue to follow NCCN and other guideline-body direction on RCC risk stratification independent of reimbursement status. For test developers, the six-point pathway above is the clearest public signal yet of what a resubmission would need: prospective or contemporary validation cohorts reflecting current immunotherapy-era treatment, head-to-head performance data against nomograms already in clinical use, and peer-reviewed utility evidence rather than retrospective association data. For broader background on how LCDs, NCDs, and the MolDX technical assessment process fit together, see our guide to Medicare coverage for genetic testing, and for a look at how the same late-August MolDX batch handled a genuinely new methodology, see our coverage of MolDX's optical genome mapping proposal for blood cancers. RCC is not the only solid-tumor prognostic classifier MolDX has had to weigh against thin or aging evidence — our report on MolDX's delayed DCIS biomarker coverage decision covers a parallel fight playing out in breast oncology. ScreenMyGene tracks these evidentiary shifts across MolDX's LCD portfolio as part of its broader work helping labs and clinicians navigate genetic test coverage.
Frequently asked questions
Does Medicare currently cover transcriptional biomarker testing for renal cell carcinoma?
No. Under MolDX's draft LCD DL40429, transcriptional biomarker tests used for therapeutic decision-making in renal carcinoma are non-covered, based on evidence MolDX judged retrospective, outdated, and skewed toward clear-cell histology.
Is DL40429 final, or can it still change?
DL40429 is a draft/determination MolDX issued as part of a late-August 2026 batch of coverage decisions. Labs and stakeholders affected by the scope or reasoning should track the CMS Medicare Coverage Database directly for the document's current status and any comment period before treating it as final.
Why did MolDX cover two other tests in the same batch but not this one?
The hematologic malignancy NGS LCD (DL40425) and the genome-wide structural-variant LCD (DL40407) had stronger, more current supporting evidence for their specific claims. MolDX's own language ties the RCC denial to evidence quality and timeliness, not to genetic testing broadly.
Can an RCC prognostic biomarker test become Medicare-coverable in the future?
Yes. MolDX outlined six specific conditions — including independent validation, demonstrated clinical utility in peer-reviewed literature, and comparable performance to existing tools — that a future submission would need to satisfy.
Does this decision affect other genomic or molecular testing in kidney cancer, such as hereditary cancer panels?
No. DL40429 is specific to transcriptional biomarker classifiers used for therapeutic decision-making in renal carcinoma. It does not address hereditary cancer germline testing, tumor mutation profiling for targeted therapy selection, or other molecular testing categories in renal cancer.
This article summarizes publicly available Medicare coverage documentation and third-party regulatory analysis as of September 28, 2026, for general informational purposes for laboratory, revenue cycle, and clinical decision-support audiences. It is not coding, billing, legal, or reimbursement advice. Draft and recently issued LCDs are subject to revision, and coverage policy varies by Medicare Administrative Contractor and commercial payer. Confirm current policy directly with the relevant MAC before making coverage, billing, or clinical decisions.
Sources: Discoveries in Health Policy, "MolDx Issues Bonanza of New LCDs in Late August 2026" (analysis of MolDX draft LCD DL40429, "Transcriptional Biomarkers for Therapeutic Decision-Making in Renal Carcinoma," and companion LCDs DL40425 and DL40407); CMS Medicare Coverage Database, LCD L38576/L38649, "MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer."